<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: androgen receptors</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Mushroom-supplemented soybean extract shows therapeutic promise for advanced prostate cancer</title>
   	 <description>A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.</description>
     <link>http://medicalxpress.com/news/2013-02-mushroom-supplemented-soybean-therapeutic-advanced-prostate.html</link>
	 <category>Cancer</category>
	 <pubDate>Wed, 20 Feb 2013 13:23:28 EST</pubDate>
	 <guid isPermaLink="false">news280588913</guid>
	 
</item>
<item>
     <title>Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy</title>
   	 <description>Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24. A University of Colorado Cancer Center study published today in the Proceedings of the National Academy of Sciences shows that CD24 expression may depend on androgens – and that anti-androgen therapies like those currently used to treat prostate cancer may benefit bladder cancer patients.</description>
     <link>http://medicalxpress.com/news/2012-09-prostate-cancer-bladder-patients-benefit.html</link>
	 <category>Cancer</category>
	 <pubDate>Mon, 24 Sep 2012 15:00:06 EST</pubDate>
	 <guid isPermaLink="false">news267704662</guid>
	 
</item>
<item>
     <title>Enzalutamide adds five months survival in late-stage prostate cancer</title>
   	 <description>Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.</description>
     <link>http://medicalxpress.com/news/2012-08-enzalutamide-months-survival-late-stage-prostate.html</link>
	 <category>Cancer</category>
	 <pubDate>Thu, 16 Aug 2012 10:33:22 EST</pubDate>
	 <guid isPermaLink="false">news264331988</guid>
	 
</item>
<item>
     <title>New target, new drug in breast cancer</title>
   	 <description>Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.</description>
     <link>http://medicalxpress.com/news/2012-06-drug-breast-cancer.html</link>
	 <category>Cancer</category>
	 <pubDate>Mon, 04 Jun 2012 09:11:16 EST</pubDate>
	 <guid isPermaLink="false">news258019856</guid>
	 
</item>
<item>
     <title>Low testosterone levels could raise diabetes risk for men</title>
   	 <description>Low levels of testosterone in men could increase their risk of developing diabetes, a study suggests.</description>
     <link>http://medicalxpress.com/news/2012-05-testosterone-diabetes-men.html</link>
	 <category>Medical research</category>
	 <pubDate>Fri, 04 May 2012 10:50:06 EST</pubDate>
	 <guid isPermaLink="false">news255345381</guid>
	 
</item>


</channel>
</rss>
